reflux esophagitis
Conditions
Interventions
switching to esomeprazole
Sponsors
Nagasaki University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who diagnosed with Grade A or worse reflux esophagitis according to the Los Angeles Classification of endoscopic findings were eligible. Patients were eligible for the switching study if they had refractory reflux esophagitis, which was defined as scores of>= 4 (moderate or higher) for question 2 (heartburn) or question 3 (acid regurgitation) of the Global Overall Symptom (GOS) questionnaire after treatment with a conventional PPI (omeprazole, lansoprazole, or rabeprazole) for >= 8 weeks.
Exclusion criteria
Exclusion criteria: Patients with any of the following were excluded from the switching study: history of gastric resection or vagotomy; presence of vomiting, gastrointestinal bleeding (including hematemesis, melena, and anemia), or sudden weight loss; history of structural brain disorders, schizophrenia, or a predisposition to schizophrenia; known addiction to alcohol or drugs; presence of serious cardiac, hepatic, renal, or hematopoietic disorders; or a history of hypersensitivity to the ingredients of the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the proportion of patients who reported an improvement in reflux-related symptoms at 4 weeks after switching to esomeprazole | — |
Countries
Japan
Contacts
Public ContactFuminao Takeshima
Nagasaki University Hospital Gastroenterology and Hepatology
Outcome results
None listed